All In Biotech

Drug Trial Radar · NCT06909565

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 6,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

6,000

Planned (sponsor's estimate)

Start

Jul 23, 2025

Primary completion

Oct 2029

Study completion Dec 2029

Sponsor

Lead sponsor
Duke UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis Pharmaceuticals; Colorado Prevention Center; Mount Sinai Hospital, New York
First posted
Apr 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.

Conditions

  • Percutaneous Coronary Intervention
  • Peripheral Endovascular Intervention

Interventions

  • Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mLDrug

    300 mg (equivalent to 284 mg inclisiran) in 1.5 mL subcutaneous injection at Day 0; Day 90; \& every 6 months thereafter

  • Normal Saline (Placebo)Drug

    Normal saline placebo subcutaneous injection given at Day 0, Day 90; \& every 6 months thereafter

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total number of major adverse cardiovascular events (MACE) after coronary or peripheral endovascular revascularizationTime frame: From randomization to first occurrence of MACE (up to approximately 4 years)
  2. Total number of major adverse limb events (MALE) after endovascular revascularizationTime frame: From randomization to first occurrence of MALE (up to approximately 4 years)

Locations

153 sites in 1 country. Site status is shown where the registry gives one.

  • Advanced Cardiovascular LLC

    Alexander City, Alabama · Recruiting

  • Cardiology, PC

    Birmingham, Alabama · Recruiting

  • Heart Center Research, LLC

    Huntsville, Alabama · Recruiting

  • IMS Cardiology

    Avondale, Arizona · Recruiting

  • Cardiology Associates Research Group

    Jonesboro, Arkansas · Recruiting

  • Arkansas Cardiology

    Little Rock, Arkansas · Recruiting

  • Arkansas Heart Hospital

    Little Rock, Arkansas · Recruiting

  • Pacific Oaks Medical Group

    Beverly Hills, California · Recruiting

  • Cardiovascular Institute of San Diego

    Chula Vista, California · Recruiting

  • John Muir Medical Center - Concord Campus

    Concord, California · Recruiting

  • Valley Clinical Trials

    Covina, California · Withdrawn

  • Thrive Clinical Research Group

    Glendora, California · Recruiting

  • Radin Cardiovascular Medical Group, Inc

    Newport Beach, California · Recruiting

  • Amicis Research

    Northridge, California · Recruiting

  • Valley Clinical Trials, LLC - Flourish Research

    Northridge, California · Recruiting

  • Riverside Community Hospital

    Riverside, California · Recruiting

  • Kaiser Permanente - San Diego

    San Diego, California · Recruiting

  • San Diego Cardiac Center

    San Diego, California · Recruiting

  • Sutter Health Heart and Vascular

    San Francisco, California · Recruiting

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California · Recruiting

  • The Heart Medical Group

    Van Nuys, California · Recruiting

  • FOMAT - West Coast Research Center

    Ventura, California · Recruiting

  • Interventional Cardiology Medical Group

    West Hills, California · Recruiting

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Aurora Denver Cardiology Associates - Englewood

    Englewood, Colorado · Recruiting

  • ClinRe 001-001

    Thornton, Colorado · Recruiting

  • Bridgeport Hospital

    Bridgeport, Connecticut · Recruiting

  • Nuvance Health- Danbury Hospital

    Danbury, Connecticut · Recruiting

  • Cardiology Associates of Fairfield County

    Stamford, Connecticut · Recruiting

  • BayCare Medical Group

    Clearwater, Florida · Recruiting

  • Clearwater Cardiovascular Consultants

    Clearwater, Florida · Recruiting

  • Pioneer Clinical Studies

    Coral Gables, Florida · Recruiting

  • Arrow Clinical Trails

    Daytona Beach, Florida · Recruiting

  • Cardiology Research Associates

    Daytona Beach, Florida · Recruiting

  • Vascardio Research

    Hialeah, Florida · Recruiting

  • UF Health Jacksonville

    Jacksonville, Florida · Recruiting

  • East Coast Institute for Research, LLC

    Jacksonville, Florida · Recruiting

  • First Coast Cardiovascular Institute, PA

    Jacksonville, Florida · Recruiting

  • Clearwater Cardiovascular and Interventional Consultants- Bardmoor

    Largo, Florida · Recruiting

  • Inpatient Research Clinic, LLC

    Miami Lakes, Florida · Recruiting

Showing 40 of 153 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.